203 related articles for article (PubMed ID: 31495130)
1. [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities].
Liu XL; Bai J; Fan HQ; Yang YP; Yue TT; Zhang Y; Yang PY; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):644-649. PubMed ID: 31495130
[No Abstract] [Full Text] [Related]
2. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
3. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
Guman T; Sykora J
Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
[TBL] [Abstract][Full Text] [Related]
4. [Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study].
Yuan RF; Dong YJ; Li CR; Huang WR; Zhang LM; Zhu Q; Xu L; Xu YJ; Xu Q; Gao GX; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):10-15. PubMed ID: 32023748
[No Abstract] [Full Text] [Related]
5. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
Chen Z; Xia Y; Guo R; Zhang R; Qiu HR; Jin YY; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):408-413. PubMed ID: 35680599
[No Abstract] [Full Text] [Related]
6. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
Mizuguchi M; Okamoto Y; Yagi H; Kagawa K; Sekimoto E; Shibata H; Shigekiyo T; Ozaki S
Int J Hematol; 2023 May; 117(5):718-728. PubMed ID: 36692689
[TBL] [Abstract][Full Text] [Related]
7. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
Shen M; Yang G; Li X; Geng C; Huang Z; Chen W
Leuk Lymphoma; 2021 Dec; 62(12):2992-3001. PubMed ID: 34219587
[TBL] [Abstract][Full Text] [Related]
8. [Cytogenetic abnormalities and prognosis of 532 patients with multiple myeloma].
Wu H; Zhang H; He HY; Jiang H; Zhao YY; An R; He J; Li R; Lu J; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):739-743. PubMed ID: 29081188
[No Abstract] [Full Text] [Related]
9. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
Tao Y; Jin S; Yang D; Pan M; Ouyang W; Liu Y; Wang Y; Zhang W; Mi J
BMC Cancer; 2024 Apr; 24(1):406. PubMed ID: 38565996
[TBL] [Abstract][Full Text] [Related]
10. Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
Uryu H; Mishima Y; Ishihara Y; Shirouchi Y; Yamauchi N; Hirano M; Hirano K; Teramoto Y; Yoshida K; Maruyama D
J Clin Exp Hematop; 2024; 64(1):10-20. PubMed ID: 38538316
[TBL] [Abstract][Full Text] [Related]
11. [Application of the Second Revision of the International Staging System (R2-ISS) in the prognostic assessment of newly diagnosed multiple myeloma].
Yan J; Zhou DM; Shao XY; Xu Y; Chen B
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):170-177. PubMed ID: 38604794
[No Abstract] [Full Text] [Related]
12. Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia.
Combariza JF; Ordúz R; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Camargo C; Sanchez V; Mejía F; Moreno L; Ramirez C
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):601-607. PubMed ID: 35351414
[TBL] [Abstract][Full Text] [Related]
13. Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance.
Baysal M; Demirci U; Umit E; Kirkizlar HO; Atli EI; Gurkan H; Gulsaran SK; Bas V; Mail C; Demir AM
Sci Rep; 2020 Apr; 10(1):5991. PubMed ID: 32249811
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).
Kim K; Kim JS; Yoon SS; Yoon DH; Eom HS; Lee JJ; Yim HW; Park M; Lee H; Min CK;
Int J Hematol; 2022 Jul; 116(1):110-121. PubMed ID: 35543899
[TBL] [Abstract][Full Text] [Related]
15. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
17. [Prognostic Value of R-ISS Staging Combined with "Multiple-Hits" in Patients with Multiple Myeloma].
Sun HM; Zhai SS; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):158-166. PubMed ID: 33554813
[TBL] [Abstract][Full Text] [Related]
18. Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World Experience.
Thurlapati A; Wesson W; Davis JA; Gaffney KJ; Weeda E; Velayati A; Bakos JK; Granger K; Smith D; Maldonado AP; Herrington T; Potts J; Hashmi H
J Hematol; 2023 Dec; 12(6):243-254. PubMed ID: 38188477
[TBL] [Abstract][Full Text] [Related]
19. Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.
Yang P; Chen H; Liang X; Xu W; Yu S; Huang W; Yi X; Guo Q; Tian M; Yue T; Li M; Zhang Y; Zhang M; Yan Y; Hu Z; Kumar SK; Zhou F; Dai Y; Jin F
Am J Hematol; 2023 Feb; 98(2):251-263. PubMed ID: 36309982
[TBL] [Abstract][Full Text] [Related]
20. [Chromosomal Abnormalities Associated with Clinical Outcome in Patients with Newly Diagnosed Multiple Myeloma].
Chen HM; Wei W; Peng R; Shi HT; Chen XL; Zhou F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1403-1406. PubMed ID: 30295258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
